ACET - NASDAQ
Adicet Bio, Inc.
$8.15
+4.1%Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
At a Glance
Live Snapshotacet
Cash at Beginning of Period
Last Annual Value
59.40M
3-Year CAGR
-40%
5-Year CAGR
32%
10-Year CAGR
9%
Adicet Bio, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Adicet Bio, Inc. NASDAQ:ACET | 59.40M | -38.7% | -7.7% | -2.4% | |
 Gain Therapeutics, Inc. NASDAQ:GANX | 10.42M | 12.4% | 6.8% | N/A | |
 Lite Strategy, Inc. NASDAQ:LITS | 3.71M | -38.3% | -21.4% | N/A | |
 Adverum Biotechnologies, Inc. NASDAQ:ADVM | 76.98M | 2.8% | 3.9% | -10.0% | |
 ALX Oncology Holdings Inc. NASDAQ:ALXO | 17.63M | -28.8% | -47.3% | N/A | |
 Fractyl Health, Inc. Common Stock NASDAQ:GUTS | 71.72M | 10.2% | 19.8% | N/A | |
 ImageneBio Inc NASDAQ:IMA | 12.12M | -41.3% | -40.6% | N/A | |
 Pliant Therapeutics, Inc. NASDAQ:PLRX | 72.67M | 29.2% | 7.4% | N/A | |
 Shattuck Labs, Inc. NASDAQ:STTK | 57.39M | 6.6% | -18.3% | N/A | |
 TScan Therapeutics, Inc. NASDAQ:TCRX | 183.72M | 13.7% | 39.0% | N/A | |
 Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | 40.02M | 10.2% | 82.3% | N/A |
Adicet Bio, Inc. Fair Value Envelope
Related Guides
Continue your ACET research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.